[{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody-drug Conjugate","year":"2022","type":"Licensing Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Xbrane Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xbrane Biopharma \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"Xbrane Biopharma \/ Biogen"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2021","type":"Collaboration","leadProduct":"Efgartigimod","moa":"||IgG-mediated immune response","graph1":"Immunology","graph2":"Preclinical","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansa Biopharma \/ Argenx","highestDevelopmentStatusID":"4","companyTruncated":"Hansa Biopharma \/ Argenx"},{"orgOrder":0,"company":"Amniotics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"PulmoStem","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Amniotics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amniotics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Amniotics \/ Undisclosed"},{"orgOrder":0,"company":"BioInvent","sponsor":"Cantargia AB","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"BioInvent \/ Cantargia AB","highestDevelopmentStatusID":"4","companyTruncated":"BioInvent \/ Cantargia AB"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The new results show potent activity of a CAN10 surrogate antibody, which reduced inflammation and fibrosis in three different preclinical in vivo models of systemic sclerosis.

                          Product Name : CAN10

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          August 11, 2022

                          Lead Product(s) : CAN10

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Under the terms of the agreement, Biogen will gain exclusive global regulatory, manufacturing, and commercial rights to Xcimzaneâ„¢ and will be the Marketing Authorization Holder.

                          Product Name : Xcimzane

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : $8.0 million

                          July 02, 2022

                          Lead Product(s) : Certolizumab Pegol

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Biogen

                          Deal Size : $88.0 million

                          Deal Type : Licensing Agreement

                          blank

                          03

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The funds will now be deployed to advance the company's preclinical portfolio of cell therapy candidates based on mesenchymal stem cells (MSC) from amniotic fluid. Lead candidate PulmoStemâ„¢, a first-in-class treatment for pulmonary disease is scheduled...

                          Product Name : PulmoStem

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          December 07, 2021

                          Lead Product(s) : PulmoStem

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : $6.9 million

                          Deal Type : Public Offering

                          blank

                          04

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The preclinical research collaboration is set up to explore the potential of combining imlifidase, Hansa’s IgG antibody-cleaving enzyme, and efgartigimod, argenx’s FcRn antagonist, which are both in development for indications known to be driven by d...

                          Product Name : Idefirix

                          Product Type : Enzyme

                          Upfront Cash : Undisclosed

                          March 29, 2021

                          Lead Product(s) : Imlifidase,Efgartigimod

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Argenx

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          05

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : CAN10 is fully humanized monoclonal antibody targeting IL1RAP. BioInvent will provide process development, scale-up, supply of material for toxicological studies and clinical grade material in 1000L scale for use in phase I and II clinical trials.

                          Product Name : CAN10

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          November 26, 2020

                          Lead Product(s) : CAN10

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Cantargia AB

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank